ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $729,869 | -3.5% | 15,822 | -16.1% | 0.02% | -11.1% |
| Q1 2023 | $756,326 | +79.7% | 18,861 | +107.7% | 0.02% | +50.0% |
| Q4 2022 | $420,769 | +71.7% | 9,082 | +53.8% | 0.01% | +71.4% |
| Q3 2022 | $245,000 | +14.5% | 5,906 | +282.0% | 0.01% | 0.0% |
| Q4 2020 | $214,000 | -32.3% | 1,546 | -66.1% | 0.01% | +40.0% |
| Q1 2019 | $316,000 | – | 4,562 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |